Your session is about to expire
← Back to Search
225Ac-J591 for Prostate Cancer
Study Summary
This trial is testing a new cancer treatment to determine the maximum tolerated dose while minimizing side effects.
- Prostate Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 trial • 32 Patients • NCT03276572Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have active cancer that has spread to your brain or the tissues surrounding your brain.You have had a blood clot in your leg or lung within the past month.You have received treatment with at least one of the following in the past:You have a serious illness affecting your heart, lungs, brain, kidneys, liver, or blood that could make it difficult for you to complete the study or make it hard to determine if any side effects you experience are related to the study medication.You are currently taking a medication called enzalutamide, which is used to block the effects of the hormone testosterone.You are taking a medication called abiraterone acetate, which is a type of drug that inhibits CYP 17.You have another type of cancer, except for non-melanoma skin cancer. If you have completed treatment for your other cancer and your doctor thinks there is a low risk of it coming back (less than 30% chance), then you may still be eligible.
- Group 1: All Subjects
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA given clearance for 225Ac-J591 to be used in medical treatments?
"Our team at Power rated the safety of 225Ac-J591 with a score of 1 due to this being a Phase 1 trial, indicating there is sparse evidence supporting its efficacy and security."
What is the target number of participants for this clinical experiment?
"Unfortunately, no more participants can be recruited for this trial at this time. Initially appearing on October 10th 2017 and most recently updated on March 2nd 2021, applicants are directed to other avenues of research; there are currently 1321 trials recruiting patients with prostate cancer and 12 clinical studies actively seeking 225Ac-J591 test subjects."
Are there still opportunities open to participants in this research?
"According to the clinicaltrials.gov platform, this particular trial is not actively seeking patients at the moment and was last modified on March 2nd 2021. Although there are 1,333 other studies that are currently accepting participants."
What is the principal intent of this research?
"The primary endpoint of this clinical trial, which will be monitored over 100 months, is evaluating the occurrence of dose limiting toxicities (DLT). Additionally, researchers are also gathering data on overall survival after a single 225Ac-J591 dosage. Circulating tumor cells (CTC) response and patient reported outcomes (PRO) through Brief Pain Inventory score assessment have been identified as secondary objectives for evaluation."
What afflictions is 225Ac-J591 typically deployed against?
"The radioimmunotherapy drug 225Ac-J591 is clinically employed to address tumor antigens, suspected metastasis, and positron emission tomography."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger